{"id":"comparator-monotherapy-empagliflozin","safety":{"commonSideEffects":[{"rate":"8-13","effect":"Genital mycotic infections"},{"rate":"4-8","effect":"Urinary tract infections"},{"rate":"3-5","effect":"Polyuria"},{"rate":"<1","effect":"Diabetic ketoacidosis"},{"rate":"2-4","effect":"Volume depletion"}]},"_chembl":null,"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Comparator monotherapy empagliflozin","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T05:19:18.719848+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T05:19:33.815289+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T05:19:25.523715+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Comparator monotherapy empagliflozin","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T05:19:26.386671+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Sodium/glucose cotransporter 2 inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T05:19:27.027931+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2107830/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T05:19:26.934547+00:00"}},"_dailymed":null,"aiSummary":"Comparator monotherapy empagliflozin is a marketed drug developed by The George Institute, with a key composition patent expiring in 2028. A key strength of empagliflozin is its established market presence, leveraging its mechanism to address primary indications effectively. The primary risk is the patent expiry in 2028, which could lead to increased competition from generics.","mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"SGLT2 is responsible for reabsorbing filtered glucose in the proximal tubule of the nephron. By blocking this transporter, empagliflozin prevents glucose reabsorption, allowing excess glucose to be excreted in urine. This mechanism reduces blood glucose levels independently of insulin secretion or action, and also produces osmotic diuresis and modest weight loss.","oneSentence":"Empagliflozin inhibits sodium-glucose cotransporter 2 (SGLT2) in the kidney to increase urinary glucose excretion and lower blood glucose.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:19:33.990Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T05:19:33.815467+00:00","fieldsConflicting":0,"overallConfidence":0.95},"indications":{"approved":[{"name":"Type 2 diabetes mellitus"},{"name":"Heart failure with reduced ejection fraction"},{"name":"Chronic kidney disease"}]},"trialDetails":[{"nctId":"NCT05129722","phase":"PHASE4","title":"Polydiuretic Therapy for HFpEF, a Randomised Controlled Trial","status":"TERMINATED","sponsor":"The George Institute","startDate":"2022-10-01","conditions":"Heart Failure With Preserved Ejection Fraction","enrollment":3},{"nctId":"NCT00881530","phase":"PHASE2","title":"Empagliflozin (BI 10773) in Type Two Diabetes (T2D) Patients, Open Label Extension","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2009-03","conditions":"Diabetes Mellitus, Type 2","enrollment":660}],"_emaApprovals":[],"_faersSignals":[],"crossReferences":{"chemblId":"CHEMBL2107830"},"_approvalHistory":[],"publicationCount":99,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Empagliflozin, Jardiance"],"phase":"marketed","status":"active","brandName":"Comparator monotherapy empagliflozin","genericName":"Comparator monotherapy empagliflozin","companyName":"The George Institute","companyId":"the-george-institute","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T05:19:33.815467+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}